SCHEMBL13879748

SCHEMBL13879748

CCOC(=O)c1csc(OC(=O)c2csc(NC(=O)c3csc(NC(=O)OC(C)(C)C)n3)n2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.54
RAB9A P51151 6/20 0.54
NPC1 O15118 5/20 0.54
ABCB1 P08183 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
HSP90AA1 P07900 3/20 0.52
MAPT P10636 1/20 0.52
MAPK1 P28482 1/20 0.52
KDM4E B2RXH2 3/20 0.50
HPGD P15428 2/20 0.50
ALDH1A1 P00352 2/20 0.50
TSHR P16473 1/20 0.50
LMNA P02545 3/20 0.49
POLB P06746 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
EGFR P00533 1/20 0.48
GLA P06280 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4636472 0.93 SMN1; SMN2 (0.62) SMN1; SMN2RAB9ANPC1ABCB1CYP1A2
SCHEMBL3931386 0.93 SMN1; SMN2 (0.62) SMN1; SMN2RAB9ANPC1ABCB1CYP1A2
SCHEMBL465734 0.88 CYP1A2 (0.67) SMN1; SMN2RAB9ANPC1ABCB1CYP1A2
SCHEMBL14543311 0.86 SMN1; SMN2 (0.60) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C19
SCHEMBL14072174 0.86 ABCB1 (0.45) SMN1; SMN2RAB9ANPC1ABCB1CYP1A2
SCHEMBL13879846 0.85 RAB9A (0.46) SMN1; SMN2RAB9ANPC1ABCB1CYP1A2
SCHEMBL13879752 0.84 RAB9A (0.62) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C19
SCHEMBL2199922 0.83 CYP1A2 (0.60) SMN1; SMN2RAB9ANPC1ABCB1CYP1A2
SCHEMBL3933864 0.80 ABCB1 (0.49) SMN1; SMN2RAB9ANPC1ABCB1CYP1A2
SCHEMBL3932900 0.79 ABCB1 (0.49) SMN1; SMN2RAB9ANPC1ABCB1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637664-B2 Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease SPIROGEN SARL (CH) 2014-01-28 US disclosed
US-8637664-B2 Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease SPIROGEN SARL (CH) 2014-01-28 US disclosed
EP-1931671-B1 ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C][1, 4]BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE SPIROGEN LTD (GB) 2009-04-08 EP disclosed
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease SPIROGEN LIMITED (GB) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease CCNY, NR0B1, CNR1 SMN1; SMN2 1132/4885RAB9A 2266/4885NPC1 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.